The Food and Drug Administration’s rejection of Wyeth’s schizophrenia drug bifeprunox is the latest in a string of disappointments that is sapping the confidence of investors in the big drug company’s long-term growth prospects.Wyeth, of Madison, N.J., which disclosed the agency’s decision Friday, said it believes it will still win approval for bifeprunox, but acknowledged that it could take one to two years to address the FDA’s concerns and refile the application to the agency.
